

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

MELOXICAM INJECTION (III) OBTAINS DRUG REGISTRATION APPROVAL

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Meloxicam Injection (III) (the “**Product**”) developed by the Group has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China. The approved indication is “indicated for the treatment of moderate to severe pain in adults”. The Product is the first intravenously administered nanocrystal product approved in China.

Meloxicam is a highly selective non-steroidal anti-inflammatory drug. Conventional formulations are generally used for the treatment of chronic pains such as osteoarthritis and rheumatoid arthritis due to their slow onset and poor analgesic effects. Utilising novel nanotechnology, the Product reduces the drug particle size to the nanometer range, thereby enabling high-dose, rapid intravenous administration for the treatment of acute moderate to severe postoperative pain. The Product features rapid onset, strong analgesic effect, long-lasting action (24 hours), high patient compliance, and an extremely low excipient level, demonstrating a good safety profile. It is expected to become a superior treatment option for the management of acute moderate to severe pain.

The approval of the Product further enriches the Group’s product portfolio in the therapeutic area of analgesic treatment and marks another major breakthrough for the Group in the field of nanomedicine research and development.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 23 June 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.